Od 1997 był dyrektorem Biopharm Research Laboratories.
Ważniejsze publikacje Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML236-C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot 1976;29:1346-1348 Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-metgylglutaryl coenzyme A reductase by ML-236A and ML 236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976;72:323-326 Endo A, Tsujita T, Kuroda M, Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3methylglutaryl-coenzyme A reductase. Eur J Biochem 1977;77:31-36 Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A. Induction of 3-hydroxy-3methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 1978;253:1121-1128 Tsujita Y, Kuroda M, Tanzawa K,Kitano N, Endo A. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 1979; 32:307-313 Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals.